PolyPid Ltd. (NASDAQ:PYPD) Given Consensus Rating of "Buy" by Brokerages

Key Points

• PolyPid Ltd. (NASDAQ:PYPD) has received a consensus rating of "Buy" from six brokerages, with five analysts suggesting a buy and one recommending a strong buy, alongside an average 1-year price target of $12.40.
• Despite the positive ratings, PolyPid recently reported a quarterly loss of ($0.78) earnings per share, which was worse than analysts' estimates of ($0.53).
• AIGH Capital Management increased its holdings in PolyPid by 27%, reflecting institutional interest, as roughly 26.47% of the stock is owned by institutional investors and hedge funds.

Shares of PolyPid Ltd. (NASDAQ:PYPD - Get Free Report) have been given a consensus recommendation of "Buy" by the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $12.40.

Several research firms recently commented on PYPD. Wall Street Zen cut PolyPid from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. HC Wainwright reissued a "buy" rating and set a $13.00 target price on shares of PolyPid in a research note on Wednesday, August 13th. Craig Hallum reissued a "buy" rating and set a $13.00 target price (down from $15.00) on shares of PolyPid in a research note on Thursday, August 14th. Roth Capital reissued a "buy" rating on shares of PolyPid in a research note on Thursday, August 14th. Finally, JMP Securities lowered their target price on PolyPid from $16.00 to $14.00 and set a "market outperform" rating for the company in a research note on Tuesday, June 17th.

PolyPid Trading Up 0.3%

Shares of NASDAQ PYPD opened at $3.45 on Thursday. PolyPid has a twelve month low of $2.30 and a twelve month high of $3.93. The stock has a fifty day simple moving average of $3.47 and a 200-day simple moving average of $3.15. The stock has a market capitalization of $54.86 million, a PE ratio of -0.90 and a beta of 1.48.

PolyPid (NASDAQ:PYPD - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.25). On average, equities analysts predict that PolyPid will post -1.79 earnings per share for the current year.

Institutional Trading of PolyPid

An institutional investor recently raised its position in PolyPid stock. AIGH Capital Management LLC grew its holdings in shares of PolyPid Ltd. (NASDAQ:PYPD - Free Report) by 27.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,194,108 shares of the company's stock after buying an additional 253,727 shares during the period. PolyPid accounts for about 1.9% of AIGH Capital Management LLC's holdings, making the stock its 21st largest holding. AIGH Capital Management LLC owned about 11.72% of PolyPid worth $4,215,000 as of its most recent SEC filing. 26.47% of the stock is owned by institutional investors and hedge funds.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.